OncoDaily’s Post

🔥 In-Depth Insight from ESMO 2024! Prof Dr Michail Ignatiadis and Dr Elisa Agostinetto discuss the TREAT ctDNA study, exploring the potential of liquid biopsies to guide adjuvant treatment in HR+/HER2- breast cancer. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #BreastCancer #ctDNA #Oncology #CancerResearch

The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO - European Society for Medical Oncology Pashtoon Kasi #Cancer #CtDNA #ESMO #ESMOGI24 #MCRC #ColorectalCancer #OncoDaily #Oncology #ESMODailyReporter

The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology - Paolo Tarantino https://lnkd.in/gutH_7Kt #oncodaily #oncology #cancer #research #TRAIN3Trial #HER2Positive #BreastCancerResearch #BiomarkerDriven #OncologyInnovation #TheLancetOncology

I am pleased to report that our recent paper was the most viewed paper in JAMA Oncology in the last 7 days, with an increasing number of news outlets reporting on it  (https://lnkd.in/eZSUmJ8N). Link to the paper: https://lnkd.in/eV7btzJ6 Key Points Question:  When should a second colonoscopy be performed after a first colonoscopy with findings negative for colorectal adenoma, carcinoma in situ, or colorectal cancer (CRC)? Findings:  In this cohort study of 110 074 individuals with no family history of CRC and negative findings on their first screening colonoscopy (exposed group) and 1 981 332 matched individuals (control group), risks of CRC and CRC-specific death were lower for 15 years in the exposed group, suggesting that extending the screening interval from 10 to 15 years would miss only 2 CRC cases and 1 CRC-related death per 1000 individuals. Meaning:  Findings of this study suggest that the 10-year interval between colonoscopy screenings for CRC could be extended to 15 years in patients with no family history of CRC and negative findings on their first colonoscopy. #cancer #colorectal_cancer #colorectal_cancer_screening #colonoscopy #colonoscopy_interval

A pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC - Elisa Agostinetto JAMA Oncology OncoAlert #BreastCancer #Research #Cancer #HER2E #JAMAOncology #OncoDaily #Oncology #PCR #TumorSubtypes

Important meta-analysis in NPJ Journals Breast shedding light on one of the biggest unmet needs in breast oncology - Elisa Agostinetto OncoAlert #BreastCancer #BreastOncology #Cancer #OncoDaily #Oncology

A great summary by Priv.-Doz. Dr. med. Niklas Klümper Viktor Grünwald , Viktor Grünwald and team about the role of MMR/MSI - Emre Yekeduz American Society of Clinical Oncology (ASCO) #ASCO #Cancer #MMR #MSI #OncoDaily #Oncology

An overview of radiation oncology acronyms and lingo by Ria Mulherkar, MD https://lnkd.in/es7HGfAR #Cancer #OncoDaily #Oncology #RadiationOncology #UPMC

Can’t wait to join Paolo Tarantino and Helena Yu to review ADCs across solid tumors - Petros Grivas https://lnkd.in/gpGGvwuU #oncodaily #oncology #cancer #OncologyInnovation #ADCTreatment #PanCancerApproval #AACR #SolidTumors #CancerResearch

Picking PI3K mutation in Breast cancer New ASCO rapid recommendation update! Capivasertib + Fulvestrant is now recommended for HR-positive, HER2-negative metastatic breast cancer, showing significant benefits in progression-free survival. Read more https://lnkd.in/dnCXpfwY Listen to podcast on https://lnkd.in/dQnwDq96 #BreastCancer #Oncology #ASCO #TargetedTherapy #Capivasertib #Fulvestrant